查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472279

可吸入一氧化氮市场：依应用分类：2023-2032 年全球机会分析与产业预测

Inhaled Nitric Oxide Market By Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Distress Syndrome, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 179 Pages | 商品交期: 2-3个工作天内

价格

2022年全球吸入一氧化氮市场价值为8亿美元，预估2023年至2032年复合年增长率为7.7%，至2032年达到16亿美元。

吸入一氧化氮是一种治疗气体，用于管理和治疗新生儿缺氧性呼吸衰竭和持续性肺动脉高压。吸入一氧化氮是一种选择性肺血管扩张剂，可改善肺部通气良好区域的血流，改善通气和灌注匹配，并降低肺动脉高压。主要作用机转是活化平滑肌细胞中的鸟苷酸环化酶，导致环磷酸鸟苷 (cGMP) 增加和随后的血管舒张。

吸入一氧化氮市场-IMG1

吸入一氧化氮市场的成长归因于吸入一氧化氮的广泛采用，以应对新生儿缺氧性呼吸衰竭和慢性阻塞性肺病盛行率的上升。吸入一氧化氮治疗新生儿缺氧性呼吸衰竭的高采用率是推动吸入一氧化氮市场成长的关键因素。近年来，吸入一氧化氮已成为新生儿医学的重要治疗性介入，特别是因缺氧而出现呼吸窘迫的婴儿。例如，美国食品药物管理局于 1999 年推出 INOmax，并于 2019 年推出 Genosyl，用于治疗患有缺氧性呼吸衰竭并伴随肺动脉高压临床或超音波心动图核准的足月和足月婴儿（妊娠超过34 週）。

新生儿在适应子宫外的生活方面经常面临挑战，缺氧性呼吸衰竭是这段过渡时期的重要问题。吸入一氧化氮具有血管舒张作用，选择性作用于肺血管，扩张肺血管，改善供氧，降低肺动脉高压。它在增强氧气供应同时最大限度地减少潜在的全身副作用方面的有效性已被医疗专业人士广泛接受。

由于早产和先天缺陷等因素，新生儿缺氧性呼吸衰竭的盛行率不断增加，导致对有效治疗方案的需求激增，进一步推动了吸入一氧化氮的采用。此外，医疗保健提供者对吸入一氧化氮在预防和减轻缺氧引起的併发症方面的益处的认识不断提高，这有助于将其广泛纳入新生儿加护治疗方案中。因此，吸入一氧化氮治疗新生儿缺氧性呼吸衰竭的高采用率有望促进吸入一氧化氮的成长。

此外，慢性阻塞性肺病盛行率的上升预计将推动市场成长。慢性阻塞性肺病是一种由长期暴露于有害颗粒和气体（主要是烟草烟雾中的颗粒和气体）引起的进行性和衰弱性呼吸系统疾病，在全球范围内已达到令人震惊的水平。例如，国家医学图书馆 2022 年的一份报告称，全球 40 岁以上人群中慢性阻塞性肺病(COPD) 的盛行率为 10.1%。随着慢性阻塞性肺病的盛行率持续上升，迫切需要有效的治疗性介入来缓解症状并改善受影响者的整体生活品质。由于吸入一氧化氮在治疗慢性阻塞性肺病等呼吸系统疾病方面的潜力，其采用率正在迅速增加。一氧化氮的血管舒张和发炎作用使其成为改善肺功能的有希望的候选者。因此，慢性阻塞性肺病盛行率的上升预计将显着促进市场成长。

可吸入一氧化氮市场按应用和地区细分。依用途分为新生儿呼吸治疗、慢性阻塞性肺病（COPD）、急性呼吸窘迫症候群（ARDS）等。依地区划分，包括北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利等欧洲地区）、亚太地区（日本、澳洲等亚太地区）、拉丁美洲（拉丁美洲、中东其他地区）・非洲）。

相关人员的主要利益

  • 该报告提供了 2022 年至 2032 年吸入一氧化氮市场分析的细分市场、当前趋势、估计/趋势和动态的定量分析，并确定了当前吸入一氧化氮市场的机会。
  • 它提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的潜力。
  • 吸入一氧化氮市场区隔的详细分析将有助于确定市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与企业定位有助于基准化分析，并提供对市场参与企业当前地位的清晰了解。
  • 研究报告包括对区域和全球可吸入一氧化氮市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

可以使用此报告进行报告客製化（可能需要额外费用和时间表）

  • 国家、区域和全球各级的患者/流行病学资料
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 关键投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 吸入一氧化氮用于婴幼儿和新生儿肺部疾病管理的采用率很高
      • 呼吸道疾病盛行率上升
      • 医疗基础设施的进步
    • 抑制因素
      • 吸入一氧化氮高成本
    • 机会
      • 积极进行吸入一氧化氮的研发活动
  • 市场占有率分析

第四章吸入一氧化氮市场：依应用分类

  • 概述
  • 新生儿呼吸治疗
  • 慢性阻塞性肺病
  • 急性呼吸窘迫症候群
  • 其他的

第五章一氧化氮吸入市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 其他的
  • 亚太地区
    • 日本
    • 澳洲
    • 其他的
  • 拉丁美洲
    • 拉丁美洲
    • 中东/非洲

第六章 竞争状况

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022年主要企业定位

第七章 公司简介

  • Air Liquide SA
  • Linde PLC
  • Mallinckrodt plc
  • Vero Biotech LLC
  • SOL Group
  • Air Water Inc.
  • Chemix Specialty Gases and Equipment
  • Nippon Sanso Holdings Corporation
  • Chengdu Taiyu Industrial Gases Co., Ltd.
  • Sichuan Salman Chemical Products Co., Ltd
Product Code: A02681

The global inhaled nitric oxide market was valued at $0.8 billion in 2022, and is projected to reach $1.6 billion by 2032, growing at a CAGR of 7.7% from 2023 to 2032

Inhaled nitric oxide is a therapeutic gas used to manage and treat hypoxic respiratory failure or persistent pulmonary hypertension in newborns. Inhaled nitric oxide is a selective pulmonary vasodilator, meaning it helps improve blood flow to well-ventilated areas of the lung, thus improving ventilation-perfusion matching and reducing pulmonary hypertension. The primary mechanism of action involves the activation of guanylate cyclase in smooth muscle cells, leading to an increase in cyclic guanosine monophosphate (cGMP) and subsequent vasodilation.

Inhaled Nitric Oxide Market - IMG1

The growth of the inhaled nitric oxide market is attributed to the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure and rise in prevalence of chronic obstructive pulmonary disease. The high adoption of inhaled nitric oxide for neonatal hypoxic respiratory failure stands out as a major driver propelling the growth of the inhaled nitric oxide market. In recent years, inhaled nitric oxide has emerged as a crucial therapeutic intervention in the neonatal care landscape, particularly for infants experiencing respiratory distress due to hypoxic conditions. For instance, the U.S. Food and Drug Administration has approved INOmax in 1999 and Genosyl in 2019 for term and near-term infants (>34 weeks' gestation) with hypoxic respiratory failure associated with clinical or echocardiographic signs of pulmonary hypertension to improve oxygenation and lower the risk of extracorporeal membrane oxygenation.

Neonates often face challenges in adapting to extrauterine life, and hypoxic respiratory failure is a critical concern during this transitional period. Inhaled nitric oxide, with its vasodilatory properties, acts selectively on the pulmonary vasculature, improving oxygenation by dilating the pulmonary vessels and reducing pulmonary hypertension. Its efficacy in enhancing oxygen delivery while minimizing potential systemic side effects has garnered widespread acceptance among healthcare professionals.

The increased prevalence of neonatal hypoxic respiratory failure, attributed to factors such as premature birth and congenital disorders, has led to a surge in the demand for effective treatment options, further driving the adoption of inhaled nitric oxide. Moreover, the growth in awareness among healthcare providers about the benefits of inhaled nitric oxide in preventing or mitigating hypoxic-induced complications has contributed to widespread incorporation of inhaled nitric oxide into neonatal intensive care protocols. Thus, the high adoption of the inhaled nitric oxide for neonatal hypoxic respiratory failure is expected to drive the growth of the inhaled nitric oxide.

Furthermore, rise in prevalence of chronic obstructive pulmonary disease is expected to drive the growth of the market. Chronic obstructive pulmonary disease, a progressive and debilitating respiratory condition primarily caused by prolonged exposure to harmful particles or gases, such as those found in cigarette smoke, is reaching alarming levels globally. For instance, according to the 2022 report by the National Library of Medicine, it was reported that chronic obstructive pulmonary disease (COPD) has a worldwide prevalence of 10.1% in people aged 40 years or older. As the incidence of COPD continues to rise, there is an urgent demand for effective therapeutic interventions that can alleviate the symptoms and enhance the overall quality of life for affected individuals. The adoption of inhaled nitric oxide has surged owing to its potential in managing respiratory disorders, including COPD. The vasodilatory and anti-inflammatory properties of nitric oxide make it a promising candidate for improving pulmonary function. Thus, the rise in the prevalence of chronic obstructive pulmonary disease is expected to contribute significantly to the growth of the market.

The inhaled nitric oxide market is segmented on the basis of application, and region. By application, the market is classified into neonatal respiratory treatment, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, and rest of Europe), Asia-Pacific (Japan, Australia, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East and Africa).

Major key players that operate in the global inhaled nitric oxide market are Air Liquide S.A, Linde Plc, Mallinckrodt Plc, Vero Biotech LLC, Chemix Specialty Gases and Equipment, Air Water Inc, Sichuan Salman Chemical Products Co., Ltd, Linde PLC, SOL Group, Nippon Sanso Holdings Corporation and Chengdu Taiyu Industrial Gases Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inhaled nitric oxide market analysis from 2022 to 2032 to identify the prevailing inhaled nitric oxide market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the inhaled nitric oxide market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global inhaled nitric oxide market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Application

  • Neonatal Respiratory Treatment
  • Chronic Obstructive Pulmonary Disease
  • Acute Respiratory Distress Syndrome
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Air Liquide S.A.
    • Mallinckrodt plc
    • Chemix Specialty Gases and Equipment
    • Vero Biotech LLC
    • Air Water Inc.
    • Sichuan Salman Chemical Products Co., Ltd
    • Linde PLC
    • SOL Group
    • Nippon Sanso Holdings Corporation
    • Chengdu Taiyu Industrial Gases Co., Ltd.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. High adoption of the inhaled nitric oxide for management of pulmonary disorders in the infants and newborns.
      • 3.4.1.2. Rise in prevalence of the respiratory disorders.
      • 3.4.1.3. Advancements in healthcare infrastructure.
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of inhaled nitric oxide.
    • 3.4.3. Opportunities
      • 3.4.3.1. High research and development activities for inhaled nitric oxide.
  • 3.5. Market Share Analysis

CHAPTER 4: INHALED NITRIC OXIDE MARKET, BY APPLICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Neonatal Respiratory Treatment
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Chronic Obstructive Pulmonary Disease
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Acute Respiratory Distress Syndrome
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: INHALED NITRIC OXIDE MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Application
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Application
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Application
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Application
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Application
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Application
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Application
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Application
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Application
      • 5.3.3.5. Rest of Europe
      • 5.3.3.5.1. Market size and forecast, by Application
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Application
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Application
      • 5.4.3.2. Australia
      • 5.4.3.2.1. Market size and forecast, by Application
      • 5.4.3.3. Rest of Asia-Pacific
      • 5.4.3.3.1. Market size and forecast, by Application
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Application
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Latin America
      • 5.5.3.1.1. Market size and forecast, by Application
      • 5.5.3.2. Middle East And Africa
      • 5.5.3.2.1. Market size and forecast, by Application

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2022

CHAPTER 7: COMPANY PROFILES

  • 7.1. Air Liquide S.A.
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
  • 7.2. Linde PLC
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Mallinckrodt plc
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
  • 7.4. Vero Biotech LLC
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
  • 7.5. SOL Group
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
    • 7.5.7. Key strategic moves and developments
  • 7.6. Air Water Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
  • 7.7. Chemix Specialty Gases and Equipment
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. Nippon Sanso Holdings Corporation
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Chengdu Taiyu Industrial Gases Co., Ltd.
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
  • 7.10. Sichuan Salman Chemical Products Co., Ltd
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio

LIST OF TABLES

  • TABLE 01. GLOBAL INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 02. INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. INHALED NITRIC OXIDE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 06. INHALED NITRIC OXIDE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 08. NORTH AMERICA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 09. U.S. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 10. CANADA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 11. MEXICO INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 12. EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 13. EUROPE INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 14. GERMANY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 15. FRANCE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. UK INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 17. ITALY INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 18. REST OF EUROPE INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 19. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 21. JAPAN INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 22. AUSTRALIA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 24. LAMEA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 25. LAMEA INHALED NITRIC OXIDE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 26. LATIN AMERICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 27. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 28. AIR LIQUIDE S.A.: KEY EXECUTIVES
  • TABLE 29. AIR LIQUIDE S.A.: COMPANY SNAPSHOT
  • TABLE 30. AIR LIQUIDE S.A.: PRODUCT SEGMENTS
  • TABLE 31. AIR LIQUIDE S.A.: PRODUCT PORTFOLIO
  • TABLE 32. LINDE PLC: KEY EXECUTIVES
  • TABLE 33. LINDE PLC: COMPANY SNAPSHOT
  • TABLE 34. LINDE PLC: PRODUCT SEGMENTS
  • TABLE 35. LINDE PLC: PRODUCT PORTFOLIO
  • TABLE 36. LINDE PLC: KEY STRATERGIES
  • TABLE 37. MALLINCKRODT PLC: KEY EXECUTIVES
  • TABLE 38. MALLINCKRODT PLC: COMPANY SNAPSHOT
  • TABLE 39. MALLINCKRODT PLC: PRODUCT SEGMENTS
  • TABLE 40. MALLINCKRODT PLC: PRODUCT PORTFOLIO
  • TABLE 41. VERO BIOTECH LLC: KEY EXECUTIVES
  • TABLE 42. VERO BIOTECH LLC: COMPANY SNAPSHOT
  • TABLE 43. VERO BIOTECH LLC: PRODUCT SEGMENTS
  • TABLE 44. VERO BIOTECH LLC: PRODUCT PORTFOLIO
  • TABLE 45. SOL GROUP: KEY EXECUTIVES
  • TABLE 46. SOL GROUP: COMPANY SNAPSHOT
  • TABLE 47. SOL GROUP: PRODUCT SEGMENTS
  • TABLE 48. SOL GROUP: PRODUCT PORTFOLIO
  • TABLE 49. SOL GROUP: KEY STRATERGIES
  • TABLE 50. AIR WATER INC.: KEY EXECUTIVES
  • TABLE 51. AIR WATER INC.: COMPANY SNAPSHOT
  • TABLE 52. AIR WATER INC.: PRODUCT SEGMENTS
  • TABLE 53. AIR WATER INC.: PRODUCT PORTFOLIO
  • TABLE 54. CHEMIX SPECIALTY GASES AND EQUIPMENT: KEY EXECUTIVES
  • TABLE 55. CHEMIX SPECIALTY GASES AND EQUIPMENT: COMPANY SNAPSHOT
  • TABLE 56. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT SEGMENTS
  • TABLE 57. CHEMIX SPECIALTY GASES AND EQUIPMENT: PRODUCT PORTFOLIO
  • TABLE 58. NIPPON SANSO HOLDINGS CORPORATION: KEY EXECUTIVES
  • TABLE 59. NIPPON SANSO HOLDINGS CORPORATION: COMPANY SNAPSHOT
  • TABLE 60. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT SEGMENTS
  • TABLE 61. NIPPON SANSO HOLDINGS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 62. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: KEY EXECUTIVES
  • TABLE 63. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: COMPANY SNAPSHOT
  • TABLE 64. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT SEGMENTS
  • TABLE 65. CHENGDU TAIYU INDUSTRIAL GASES CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 66. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: KEY EXECUTIVES
  • TABLE 67. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: COMPANY SNAPSHOT
  • TABLE 68. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT SEGMENTS
  • TABLE 69. SICHUAN SALMAN CHEMICAL PRODUCTS CO., LTD: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. INHALED NITRIC OXIDE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF INHALED NITRIC OXIDE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN INHALED NITRIC OXIDE MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN INHALED NITRIC OXIDE MARKET (2023-2032)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL INHALED NITRIC OXIDE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. INHALED NITRIC OXIDE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR NEONATAL RESPIRATORY TREATMENT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR ACUTE RESPIRATORY DISTRESS SYNDROME, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF INHALED NITRIC OXIDE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. INHALED NITRIC OXIDE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 17. U.S. INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 18. CANADA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 19. MEXICO INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 20. GERMANY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 21. FRANCE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 22. UK INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. ITALY INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. REST OF EUROPE INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. JAPAN INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. AUSTRALIA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. REST OF ASIA-PACIFIC INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. LATIN AMERICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. MIDDLE EAST AND AFRICA INHALED NITRIC OXIDE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. TOP WINNING STRATEGIES, BY YEAR (2020-2021)
  • FIGURE 31. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2021)
  • FIGURE 32. TOP WINNING STRATEGIES, BY COMPANY (2020-2021)
  • FIGURE 33. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 34. COMPETITIVE DASHBOARD
  • FIGURE 35. COMPETITIVE HEATMAP: INHALED NITRIC OXIDE MARKET
  • FIGURE 36. TOP PLAYER POSITIONING, 2022
  • FIGURE 37. AIR LIQUIDE S.A.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 38. AIR LIQUIDE S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 39. AIR LIQUIDE S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 40. LINDE PLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 41. LINDE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 42. LINDE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 43. MALLINCKRODT PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. MALLINCKRODT PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. MALLINCKRODT PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. SOL GROUP: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. SOL GROUP: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 48. SOL GROUP: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 49. AIR WATER INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. AIR WATER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. NIPPON SANSO HOLDINGS CORPORATION: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. NIPPON SANSO HOLDINGS CORPORATION: REVENUE SHARE BY SEGMENT, 2022 (%)